Are we ignoring the dilated thoracic aorta?

Annals of the New York Academy of Sciences

Volumn 1254, Issue 1, 2012, Pages 164-174

  Castellano, Jose M ^a   Kovacic, Jason C ^a   Sanz, Javier ^a   Fuster, Valentin ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Cardiovascular risk factors; Dilated thoracic aorta; Thoracic aortic aneurysm

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELIPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; FIBRILLIN 1; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROXITHROMYCIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA;

ANEURYSM SURGERY; ANTIBIOTIC THERAPY; AORTA COARCTATION; AORTA DISSECTION; ARTICLE; AUTOIMMUNE DISEASE; BICUSPID AORTIC VALVE; BLOOD VESSEL TONE; CLEFT PALATE; COMPUTER ASSISTED TOMOGRAPHY; EHLERS DANLOS SYNDROME; ELASTOLYSIS; EXTRACELLULAR MATRIX; FAMILIAL DISEASE; GENE MUTATION; GROWTH RATE; HEART INFARCTION; HUMAN; HYPERTELORISM; HYPOPLASTIC LEFT HEART SYNDROME; LOEYS DIETZ SYNDROME; MARFAN SYNDROME; THORACIC AORTA ANEURYSM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT INDICATION;

EID: 84860466698     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06493.x     Document Type: Article

References (47)

1. Liao, S.L., S. Elmariah, S. van der Zee, et al 2010. Does medical therapy for thoracic aortic aneurysms really work? Are beta-blockers truly indicated? CON. Cardiol. Clin. 28: 261-269.
2. Elefteriades, J.A. 2008. Thoracic aortic aneurysm: reading the enemy's playbook. Curr. Prob. Cardiol. 33: 203-277.
3. Bickerstaff, L.K. et al 1982. Thoracic aortic aneurysms: a population-based study. Surgery 92: 1103-1108.
4. Homme, J.L. et al 2006. Surgical pathology of the ascending aorta: a clinicopathologic study of 513 cases. Am. J. Surg. Pathol. 30: 1159-1168.
5. Nienaber, C.A. & K.A. Eagle 2003. Aortic dissection: new frontiers in diagnosis and management: Part I: from etiology to diagnostic strategies. Circulation 108: 628-635.
6. Ramanath, V.S., J.K. Oh, T.M. Sundt 3rd & K.A. Eagle 2009. Acute aortic syndromes and thoracic aortic aneurysm. Mayo Clin. Proc. 84: 465-481.
7. Acosta, S. et al 2006. Increasing incidence of ruptured abdominal aortic aneurysm: a population-based study. J. Vasc. Surg. 44: 237-243.
8. Clouse, W.D. et al 1998. Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA 280: 1926-1929.
9. Svensson, L.G. & E.R. Rodriguez 2005. Aortic organ disease epidemic, and why do balloons pop? Circulation 112: 1082-1084.
10. Elefteriades, J.A. & E.A. Farkas 2010. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J. Am. Coll. Cardiol. 55: 841-857.
11. Loeys, B.L. et al 2010. The revised Ghent nosology for the Marfan syndrome. J. Med. Genet. 47: 476-485.
12. Judge, D.P. & H.C. Dietz 2008. Therapy of Marfan syndrome. Annu. Rev. Med. 59: 43-59.
13. Canadas, V., I. Vilacosta, I. Bruna & V. Fuster 2010. Marfan syndrome. Part 1: pathophysiology and diagnosis. Nature reviews. Cardiology 7: 256-265.
14. Canadas, V., I. Vilacosta, I. Bruna & V. Fuster 2010. Marfan syndrome. Part 2: treatment and management of patients. Nat. Rev. Cardiol. 7: 266-276.
15. Hiratzka, L.F. et al 2010. ACCF/AHA/AATS/ACR/ ASA/ SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 121: e266-369.
16. Loeys, B.L. et al 2006. Aneurysm syndromes caused by mutations in the TGF-beta receptor. New Engl. J. Med. 355: 788-798.
17. Garg, V. et al 2005. Mutations in NOTCH1 cause aortic valve disease. Nature 437: 270-274.
18. El-Hamamsy, I. & M.H. Yacoub 2009. A measured approach to managing the aortic root in patients with bicuspid aortic valve disease. Curr. Cardiol. Rep. 11: 94-100.
19. Biner, S. et al 2009. Aortopathy is prevalent in relatives of bicuspid aortic valve patients. J. Am. Coll. Cardiol. 53: 2288-2295.
20. Loscalzo, M.L. et al 2007. Familial thoracic aortic dilation and bicommissural aortic valve: a prospective analysis of natural history and inheritance. Am. J. Med. Genet. A 143A: 1960-1967.
21. Milewicz, D.M. et al 1998. Reduced penetrance and variable expressivity of familial thoracic aortic aneurysms/dissections. Am. J. Cardiol. 82: 474-479.
22. Albornoz, G. et al 2006. Familial thoracic aortic aneurysms and dissections-incidence, modes of inheritance, and phenotypic patterns. Ann. Thorac. Surg. 82: 1400-1405.
23. Pannu, H., V. Tran-Fadulu & D.M. Milewicz 2005. Genetic basis of thoracic aortic aneurysms and aortic dissections. Am. J. Med. Genet. C 139C: 10-16.
24. Sinha, I. et al 2006. A biologic basis for asymmetric growth in descending thoracic aortic aneurysms: a role for matrix metalloproteinase 9 and 2. J. Vasc. Surg. 43: 342-348.
25. Kim, E.S., M.S. Kim & A. Moon 2004. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int. J. Oncol. 25: 1375-1382.
26. Galis, Z.S. & J.J. Khatri 2002. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90: 251-262.
27. Visse, R. & H. Nagase 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92: 827-839.
28. Ikonomidis, J.S. et al 2005. Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation 112: I242-248.
29. Wilson, W.R. et al 2006. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 113: 438-445.
30. Ikonomidis, J.S. et al 2006. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation 114: I365-370.
31. Ammash, N.M., T.M. Sundt & H.M. Connolly 2008. Marfan syndrome: diagnosis and management. Curr. Probl. Cardiol. 33: 7-39.
32. El-Hamamsy, I. & M.H. Yacoub 2009. Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat. Rev. Cardiol. 6: 771-786.
33. Nataatmadja, M., J. West & M. West 2006. Overexpression of transforming growth factor-beta is associated with increased hyaluronan content and impairment of repair in Marfan syndrome aortic aneurysm. Circulation 114: I371-377.
34. Prokop, E.K., R.F. Palmer & M.W. Wheat, Jr. 1970. Hydrodynamic forces in dissecting aneurysms. In-vitro studies in a Tygon model and in dog aortas. Circ. Res. 27: 121-127.
35. Ong, K.T. et al 2010. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet 376: 1476-1484.
36. Ejiri, J. et al 2003. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc. Res. 59: 988-996.
37. Sukhija, R., W.S. Aronow, R. Sandhu, et al 2006. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am. J. Cardiol. 97: 279-280.
38. Ferguson, C.D. et al 2010. Association of statin prescription with small abdominal aortic aneurysm progression. Am. Heart J. 159: 307-313.
39. Nieto, F.J. 2002. Infective agents and cardiovascular disease. Semin. Vasc. Med. 2: 401-415.
40. Lindholt, J.S., H.A. Ashton & R.A. Scott 2001. Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms. J. Vasc. Surg. 34: 212-215.
41. Curci, J.A. et al 2000. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J. Vasc. Surg. 31: 325-342.
42. Vammen, S., J.S. Lindholt, L. Ostergaard, et al 2001. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br. J. Surg. 88: 1066-1072.
43. Longo, G.M. et al 2005. MMP-12 has a role in abdominal aortic aneurysms in mice. Surgery 137: 457-462.
44. Prall, A.K. et al 2002. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J. Vasc. Surg. 35: 923-929.
45. Baxter, B.T. et al 2002. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J. Vasc. Surg. 36: 1-12.
46. Mosorin, M. et al 2001. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J. Vasc. Surg. 34: 606-610.
47. Habashi, J.P. et al 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312: 117-121.